Anakinra 100 mg + Triamcinolone Acetonide 40 mg + Placebo to Anakinra 100 mg + Placebo to Triamcinolone Acetonide 40 mg
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Acute Gouty Arthritis
Conditions
Acute Gouty Arthritis
Trial Timeline
Dec 1, 2016 → Aug 1, 2019
NCT ID
NCT03002974About Anakinra 100 mg + Triamcinolone Acetonide 40 mg + Placebo to Anakinra 100 mg + Placebo to Triamcinolone Acetonide 40 mg
Anakinra 100 mg + Triamcinolone Acetonide 40 mg + Placebo to Anakinra 100 mg + Placebo to Triamcinolone Acetonide 40 mg is a phase 2 stage product being developed by Swedish Orphan Biovitrum for Acute Gouty Arthritis. The current trial status is completed. This product is registered under clinical trial identifier NCT03002974. Target conditions include Acute Gouty Arthritis.
What happened to similar drugs?
20 of 20 similar drugs in Acute Gouty Arthritis were approved
Approved (20) Terminated (4) Active (0)
✅Modification of Prasugrel based on a biological assay + prasugrel / clopidogrelDaiichi SankyoApproved
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03002974 | Phase 2 | Completed |
Competing Products
20 competing products in Acute Gouty Arthritis